Loading company…
SCAI THERAPEUTICS develops drug delivery technology to improve drug bioavailability.
Founded in 2019 and based in Seoul, South Korea, SCAI THERAPEUTICS develops pharmaceutical technology to improve drug bioavailability. Its MOASIS platform creates molecular clusters from small molecules. In July 2026, it raised KRW 13 billion in Series C funding from BonAngels Venture Partners, Solid X, and other investors to support phase two trials for a wet macular degeneration treatment and production systems for cosmetic raw materials and sunscreen boosters.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in